Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)

This study is testing blood biomarkers (substances measurable in the blood) to see if they can detect liver cancer (hepatocellular carcinoma, or HCC) at an early stage — before it becomes visible on standard imaging. Early detection is critical for improving survival rates in liver cancer. **You may be eligible if:** - You are a patient newly diagnosed with liver cancer (HCC) arising from cirrhosis or another liver condition (case group), OR - You are a patient with liver cirrhosis or chronic hepatitis being monitored for liver cancer but without a current diagnosis (control group) **You may NOT be eligible if:** - You are currently taking warfarin (a blood thinner), as it can interfere with one of the blood markers being tested and produce misleading results Talk to your doctor to see if this trial is right for you.